Cantor Fitzgerald analyst Elemer Piros maintained a Buy rating on Aldeyra Therapeutics (ALDX) today and set a price target of $30. The company’s shares closed yesterday at $10.09.
Piros said:
“Aldeyra develops a platform of aldehyde trap therapies for the potential treatment of inflammation in ocular diseases and inborn errors of aldehyde metabolism. We believe Aldeyra’s is poised for several near term catalysts over the next 12 months. Valuation Summary We arrive at our 12-month price target of $30/share by assessing the after-tax, risk- adjusted NPV of future cash flows from reproxalap, the platform and year-end 2019 cash.”
According to TipRanks.com, Piros is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -11.1% and a 31.2% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Proteostasis Therapeutics Inc, and Strongbridge Biopharma Plc.
Aldeyra Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $33.67.
See today’s analyst top recommended stocks >>
Based on Aldeyra Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $9.05 million. In comparison, last year the company had a GAAP net loss of $4.99 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes.
Read More on ALDX:
